Market Overview:
The global protein phosphatase 2A market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, rising demand for novel therapies, and growing investments by pharmaceutical companies in R&D activities. Based on type, the global protein phosphatase 2A market is segmented into LB-100, NCE-001, PEP-010, RP-0217 and others. LB-100 held the largest share of the global protein phosphatase 2A market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy as a therapeutic agent against various types of cancer. Based on application, hepatocellular carcinoma held the largest share of the global protein phosphatase 2A market in 2017 and is expected to maintain its dominance duringthe forecast period.
Product Definition:
Protein phosphatase 2A (PP2A) is a protein that in humans is encoded by the PPP2R1B gene. PP2A is a large and complex enzyme that catalyzes the dephosphorylation of many proteins, including transcription factors, kinases, and phosphatases. The importance of PP2A lies in its ability to regulate the activity of other enzymes by removing their phosphate groups.
LB-100:
LB-100, also known as Lamin B or CD99 is a protein phosphatase 2A. It is an enzyme that removes phosphate from various substrates including proteins, nucleic acids and lipids. The product has wide applications in research laboratories for the study of cellular processes such as signal transduction pathways and gene expression.
NCE-001:
The NCE-001 is a novel chemical entity developed by the pharmaceutical company Pfizer. The drug was first registered under the name of Cantel Medical, in 2016, and later rebranded as NCE-001 by Pfizer. It is currently in phase II clinical trials for treating patients with advanced melanoma who have suffered from resistance to traditional chemotherapies such as 5-fluorouracil and methotrexate.
Application Insights:
The lung cancer segment dominated the market in terms of revenue share in 2017. The growth can be attributed to the increasing prevalence of smoking and non-smokers exposed to second-hand tobacco smoke. Lung cancer is one of the most common cancers worldwide, affecting nearly 50 million people annually. It is estimated that around 17% of global deaths occur due to lung cancer every year.
Hepatocellular carcinoma (HCC) is expected to emerge as a prominent application over the forecast period owing to its high incidence rate and mortality rate globally; 1 out of 5 liver tumors are diagnosed with HCC which leads to death or disability each year globally. In addition, there are other applications such as breast tumorigenesis and others that contribute towards revenue generation for this industry despite their low incidence rates compared with HCC or other oncology indications such as prostate & breast carcinoma etc.
Regional Analysis:
North America dominated the global protein phosphatase 2A market in 2017. This can be attributed to the presence of a large number of protein phosphatase 2A manufacturers and suppliers, increased R&D investment by companies, and high healthcare expenditure in this region. Moreover, increasing prevalence of cancer is also expected to drive growth over the forecast period. For instance, according to statistics published by American Cancer Society in 2018, around 1.7 million people were diagnosed with new cases of cancer in U.S., including lung (471), liver (329), prostate (274), colon/rectum (246) and breast tumors).
Growth Factors:
- Increasing demand for better quality food products with enhanced nutritional value is expected to drive the growth of the protein phosphatase 2A market over the forecast period.
- Growing awareness about the health benefits associated with consuming protein phosphatase 2A is anticipated to boost demand for these enzymes in the coming years.
- The increasing application of protein phosphatase 2A in various end-use industries such as pharmaceuticals, biotechnology, and nutraceuticals is projected to fuel market growth over the next few years.
- Rising investments by key players in research and development activities aimed at enhancing product offerings is likely to propel Protein Phosphatase 2A market growth during the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Protein Phosphatase 2A Market Research Report
By Type
LB-100, NCE-001, PEP-010, RP-0217, Others
By Application
Hepatocellular Carcinoma, Lung Cancer, Breast Tumor, Others
By Companies
Ampio Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cyano Biotech GmbH, Lixte Biotechnology Holdings, Inc., Signum Biosciences, Inc., Ampio Pharmaceuticals, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
217
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Protein Phosphatase 2A Market Report Segments:
The global Protein Phosphatase 2A market is segmented on the basis of:
Types
LB-100, NCE-001, PEP-010, RP-0217, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatocellular Carcinoma, Lung Cancer, Breast Tumor, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ampio Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Cyano Biotech GmbH
- Lixte Biotechnology Holdings, Inc.
- Signum Biosciences, Inc.
- Ampio Pharmaceuticals, Inc.
Highlights of The Protein Phosphatase 2A Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- LB-100
- NCE-001
- PEP-010
- RP-0217
- Others
- By Application:
- Hepatocellular Carcinoma
- Lung Cancer
- Breast Tumor
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Protein Phosphatase 2A Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Protein phosphatase 2A is an enzyme that catalyzes the hydrolysis of protein phosphates. This activity is important for the proper functioning of cells and tissues, as it helps to break down proteins into their constituent amino acids. Protein phosphatase 2A is also involved in the regulation of cell growth and division.
Some of the key players operating in the protein phosphatase 2a market are Ampio Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cyano Biotech GmbH, Lixte Biotechnology Holdings, Inc., Signum Biosciences, Inc., Ampio Pharmaceuticals, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Protein Phosphatase 2A Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Protein Phosphatase 2A Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Protein Phosphatase 2A Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Protein Phosphatase 2A Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Protein Phosphatase 2A Market Size & Forecast, 2020-2028
4.5.1 Protein Phosphatase 2A Market Size and Y-o-Y Growth
4.5.2 Protein Phosphatase 2A Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 LB-100
5.2.2 NCE-001
5.2.3 PEP-010
5.2.4 RP-0217
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hepatocellular Carcinoma
6.2.2 Lung Cancer
6.2.3 Breast Tumor
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Protein Phosphatase 2A Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Protein Phosphatase 2A Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 LB-100
9.6.2 NCE-001
9.6.3 PEP-010
9.6.4 RP-0217
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hepatocellular Carcinoma
9.10.2 Lung Cancer
9.10.3 Breast Tumor
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 LB-100
10.6.2 NCE-001
10.6.3 PEP-010
10.6.4 RP-0217
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hepatocellular Carcinoma
10.10.2 Lung Cancer
10.10.3 Breast Tumor
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 LB-100
11.6.2 NCE-001
11.6.3 PEP-010
11.6.4 RP-0217
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hepatocellular Carcinoma
11.10.2 Lung Cancer
11.10.3 Breast Tumor
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 LB-100
12.6.2 NCE-001
12.6.3 PEP-010
12.6.4 RP-0217
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hepatocellular Carcinoma
12.10.2 Lung Cancer
12.10.3 Breast Tumor
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 LB-100
13.6.2 NCE-001
13.6.3 PEP-010
13.6.4 RP-0217
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hepatocellular Carcinoma
13.10.2 Lung Cancer
13.10.3 Breast Tumor
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Protein Phosphatase 2A Market: Competitive Dashboard
14.2 Global Protein Phosphatase 2A Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ampio Pharmaceuticals, Inc.
14.3.2 Bristol-Myers Squibb Company
14.3.3 Cyano Biotech GmbH
14.3.4 Lixte Biotechnology Holdings, Inc.
14.3.5 Signum Biosciences, Inc.
14.3.6 Ampio Pharmaceuticals, Inc.
